» Articles » PMID: 25618218

Clinical Significance of IPF% or RP% Measurement in Distinguishing Primary Immune Thrombocytopenia from Aplastic Thrombocytopenic Disorders

Overview
Journal Int J Hematol
Specialty Hematology
Date 2015 Jan 26
PMID 25618218
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The diagnosis of primary immune thrombocytopenia (ITP) is based on differential diagnosis. Although the measurement of percentages of reticulated platelets (RP%) by flow cytometry is useful as a supportive diagnostic test, this method is nonetheless a time-consuming, laboratory-based assay. To identify alternative assays that are useful in daily practice, we compared three methods in parallel, IPF% measured by XE-2100 [IPF% (XE), Sysmex Corp.], IPF% measured by new XN-1000 [IPF% (XN)], and RP%. We examined 47 patients with primary ITP, 28 patients with aplastic thrombocytopenia (18 aplastic anemia and 10 chemotherapy-induced thrombocytopenia) and 80 healthy controls. In a selected experiment, we examined 16 patients with paroxysmal nocturnal hemoglobinuria (PNH) to examine the effect of hemolysis. As compared with IPF% (XE), IPF% (XN) showed better within-run reproducibility. The sensitivity and specificity for the diagnosis of ITP were 83.0 and 75.0 % for IPF% (XE), 85.1 and 89.3 % for IPF% (XN), and 93.6 and 89.3 % for RP%, respectively. Examination of PNH patients revealed that hemolysis and/or red blood cell fragments interfered with IPF% (XE) values, but not with IFP % (XN) values. Our results suggest that IPF% measured by XN-1000 may be of comparable value with RP% as a supportive diagnostic test for ITP.

Citing Articles

Utility of immature platelet fraction in the Sysmex XN-1000V for the differential diagnosis of central and peripheral thrombocytopenia in dogs and cats.

Perez-Ecija A, Martinez C, Fernandez-Castaner J, Mendoza F J Vet Intern Med. 2024; 38(3):1512-1519.

PMID: 38619127 PMC: 11099766. DOI: 10.1111/jvim.17074.


Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.

Kashiwagi H, Kuwana M, Murata M, Shimada N, Takafuta T, Yamanouchi J Int J Hematol. 2023; 119(1):1-13.

PMID: 37957517 PMC: 10770234. DOI: 10.1007/s12185-023-03672-1.


How we treat primary immune thrombocytopenia in adults.

Liu X, Hou Y, Hou M J Hematol Oncol. 2023; 16(1):4.

PMID: 36658588 PMC: 9850343. DOI: 10.1186/s13045-023-01401-z.


Infrequent Thrombotic Complications in Japanese Patients with Warm Autoimmune Hemolytic Anemia.

Higuchi T, Hoshi T, Toriyama M, Nakajima A, Haruki K Intern Med. 2022; 62(10):1441-1447.

PMID: 36171129 PMC: 10258113. DOI: 10.2169/internalmedicine.0541-22.


Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma.

Nishikawa Y, Nishida S, Kuroda K, Kashiwagi H, Tomiyama Y, Kuwana M Diagnostics (Basel). 2022; 12(2).

PMID: 35204403 PMC: 8871323. DOI: 10.3390/diagnostics12020313.


References
1.
McMillan R . The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2008; 44(4 Suppl 5):S3-S11. DOI: 10.1053/j.seminhematol.2007.11.002. View

2.
. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987; 70(6):1718-21. View

3.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold D . Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2008; 113(11):2386-93. DOI: 10.1182/blood-2008-07-162503. View

4.
Cines D, Blanchette V . Immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13):995-1008. DOI: 10.1056/NEJMra010501. View

5.
Tomiyama Y, Kosugi S . Autoantigenic epitopes on platelet glycoproteins. Int J Hematol. 2005; 81(2):100-5. DOI: 10.1532/ijh97.04193. View